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A spontaneous remission of symptoms in women with multiple sclerosis is often associated 
with pregnancy. Sex hormones such are thought to play a crucial role in this. Both testosterone 
and estrogen have been studied extensively in the disease, but not relaxin.  In an initial study 
of relaxin in multiple sclerosis elevated levels were detected in the sera of some, but not all sub-
jects. Unfortunately, it was not possible to determine if this was relaxin 1, 2 or 3 due to the non-
specificity of the assay. In this study we measured the levels of all three relaxins in matched 
sera and cerebral spinal fluid samples from subjects with multiple sclerosis.  No relaxin 2 was 
detected in any of the samples. However, both relaxin 1 and 3 were detected in some of the 
samples. The presence of relaxin 3 was not remarkable. In contrast, the presence of relaxin 1 
was notable. The presence of relaxin 1 in subjects with multiple sclerosis suggests that it has a 
biological function and is not a pseudogene has been previously suggested. 
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Introduction
Multiple sclerosis (MS) is an inflammatory, autoimmune disease of the central 
nervous system (CNS). The disease course of MS can be either a relapsing, remitting 
or progressive form (Goldberrg, 2012). In women with the relapsing, remitting form 
of MS, the disease symptoms often go into spontaneous remission during pregnan-
cy (Lorenzi and Ford, 2002). This has engendered research into the role of sex hor-
mones in MS, most notably estrogen (Gold and Vosckuhl, 2009). Estrogens have also 
been shown to work synergistically with another sex hormone, relaxin (RLN, Huang 
and Anderson, 1997) and can regulate the mRNA expression of the relaxin receptor 
1 (RXFP1, Maseelall, 2009). Since RLN is expression is increased during pregnancy, 
could its synergistic actions with estrogen play a role in the remission of symptoms? 
There had been no studies on RLN in subjects with MS published before. Thus a 
baseline study was undertaken to determine the levels of circulating relaxin in non-
pregnant subjects with MS. In this study we reported on measurable levels of the 
pregnancy hormone RLN in the sera of some subjects with MS (Garvin and Burns, 
2016).  However, the ELISA used to detect RLN in these samples was non-specific 
and detected both RLN 1 and 2. Because of this it was unclear if the RLN detected in 
these samples was RLN 1 or 2.
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In the present study we used ELISA kits 
specific for RLN 1, 2 and 3 to determine the 
levels of each member of the RLN family in 
matched sera and cerebral spinal fluid (CSF) 
samples from subjects with MS. 
Methods
Samples
Sera and CSF samples were obtained 
from the Rocky Mountain Multiple Sclerosis 
(RMMS) Tissue Bank, Denver, Colorado (see 
Table 1). Prior to obtaining the samples, the 
project was reviewed and approved by the 
RMMS ethics review board. The samples ana-
lyzed in this study were obtained at postmor-
tem, with family consent from subjects with 
MS (n=12) and controls (n=4). Sera and CSF 
samples were then held at -800C until analysis. 
Enzyme Linked Immuno-absorbent Assays 
(ELISA)
DuoSet ELISA kits for the detection of 
human relaxin 1 & 3 were ordered from R&D 
Systems Inc., 614 McKinley Place NE, Minne-
apolis, MN. In addition to the materials pro-
vided the following solutions were required:
• Phosphate buffered saline (PBS) – 137mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 
1.5 mM KH2PO4 in distilled, deionized water. Solution was adjusted to pH 7.2-7.4 
and filtered through a 2mm filter. 
• Wash Buffer – 0.05% TweenÒ 20 in PBS, pH 7.2-7.4.
• Reagent Dilluent – 1% Bovine serum albumin in PBS, pH 7.2-7.4 filtered through a 
2mm filter.
• Substrate Solution – 1:1 Mixture of hydrogen peroxide and tetramethylbevzidine.
• Stop solution – 2 N H2SO4.
The DuoSet ELISA kits for human RLN 1 & 3 are sandwich ELISA’s and fol-
lowed the same protocol with the exception of the capture and detection antibodies 
employed. 
For RLN 1 the capture antibody used was rat anti-human RLN 1, 4.0 mg/ml in 
PBS, pH 7.2-7.4 and the detection antibody was biotinylated goat anti-human RLN1, 
400 ng/ml in reagent diluent.
For RLN 3 the capture antibody used was goat anti-human RLN 3, 1.2 mg/ml in 
PBS, pH 7.2-7.4 and the detection antibody was biotinylated goat anti-human RLN 3, 
400 ng/ml in reagent diluent.
Table 1. Characteristics of sample donors.
Sample Diagnosis Sex Age PM (hrs)
1 Control F 55 N/A
2 Control M 67 N/A
3 Control F 43 3
4 Control F 61 5.5
5 MS F 59 4.5
6 MS F 41 N/A
7 MS F 64 5.5
8 MS F 69 7
9 MS M 55 N/A
10 MS F 82 4
11 MS F 77 N/A
12 MS M 45 2
13 MS F 67 4.5
14 MS F 35 3
15 MS F 84 2.5
16 MS F 64 4
Table of sera and CSF (cerebro-spinal fluid) 
donors. The sample consisted of 4 controls (3 
females, 1 male) average age of 56.5 years. The 
MS (multiple sclerosis) subset consisted of 12 
subjects (10 female, 2 male) with and average 
age of 61.8. Samples were collected post mor-
tem (PM) and stored at -800C until assayed.
132 Roy A. Garvin
The capture antibodies were supplied as lyophilized powder and were reconsti-
tuted in PBS then diluted with PBS to the working concentration just prior to use.
The ELISA’s were performed according to the manufacturers instructions.
Plate Preparation
1. After reconstitution 100 ml of the appropriate capture antibody was added to each 
well in a 96 well microtitre plate. 
2. The plates were sealed and incubated overnight (ON) at room temperature (RT). 
The antibody solutions were aspirated off and the plates washed three times with 
400 ml of wash buffer using an autowasher. Any remaining fluid in the plates was 
removed by inverting and blotting the plate against a paper towel.
3. The plates were blocked by adding 300 ml of reagent diluent to each well. The 
plates were incubated at RT for 1 hour.
4. Plates were aspirated and washed on the autowasher and blotted dry as 
described.
Assay Procedure
1. A plate layout was followed to add 100 ml of the appropriate samples or stand-
ards to each well. The plate was then covered with a new adhesive strip and incu-
bated at RT for 2 hours. 
2. The plates were aspirated, washed on the autowasher and blotted dry as 
described.
3. Then 100 ml of the appropriate detection antibody was added to each well. The 
plates were sealed with a new adhesive strip and incubated at RT for 2 hours.
4. Plates were aspirated and washed on the autowasher and blotted dry as 
described.
5. The streptavidin conjugated to horse radish peroxidase (STD-HRP) supplied by 
the manufacturer was diluted 1:100 in diluent buffer and 100 ml added to each 
well. The plate was then covered with a new adhesive strip and placed in a dark 
chamber for 20 minutes at RT.
6. Plates were aspirated and washed on the autowasher and blotted dry as 
described.
7. After washing 100 ml of substrate solution was added to each well. The plates 
were covered with a new adhesive strip and incubated in a dark chamber for 20 
minutes at RT.
8. Finally, 50 ml of stop solution was added to each well. The plate was lightly 
tapped on the side to ensure even mixing of the solutions. 
9. The plates were immediately read at a wavelength of 450 nm in an auto-reader 
(Hewlett Packard, Palo alto, CA) using a wavelength correction reading at 540 nm. 
RLN 2 ELISA
The RLN 2 Quantikine ELISA kit was obtained from R&D Systems Inc., 614 
McKinley Place NE, Minneapolis, MN. The Quantikine ELISA was supplied with all 
reagents and pre-coated plates needed for the assay.
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Assay procedure
1. To each well 100 ml of diluent RD1-19 was added. 50ml of the appropriate stand-
ard, control or sample was then added to each well. The plate was covered with 
an adhesive strip and incubated for 2 hours at RT.
2. Plates were aspirated and washed with the wash solution provided on the auto-
washer, then blotted dry as described above.
3. To each well 200 ml of anti-RLN 2 antibody conjugated to HRP was added. The 
plate was covered with a new adhesive strip and incubated for 2 hours at RT.
4. Plates were aspirated and washed on the autowasher, then blotted dry as 
described above.
5. To each well 200 ml of substrate solution was added. The plate was covered with 
a new adhesive strip and incubated in a dark chamber for 30 minutes at RT.
6. After the final incubation 50 ml of stop solution was added to each well. 
7. The plates were immediately read at a wavelength of 450 nm in an auto-reader 
(Hewlett Packard, Palo Alto, CA) using a wavelength correction reading at 540 
nm. 
Statistical Analysis
ELISA analysis was done using the internet based software provided by ELISAkit.
com, Melbourne, Australia, http://elisaanalysis.com/. Concentrations were calcu-
lated from OD’s using 4-Parameter Logistic Regression. All significant results had a 
value of p<0.05.
Results
Measurable levels of RLN were detected in 6 of the MS subjects. No measurable 
levels of RLN were detected in any of the controls.
RLN 1 was detected in the sera and CSF of some subjects with MS (see Table 2). 
There was measurable RLN 1 in the sera of one subject (179, P<0.05) and in the CSF 
of two others (147 ng/ml, P<0.05 and 212 ng/ml, P<0.05). 
RLN 2 was not detected in the sera or CSF of any sample.
RLN 3 was detected in sera and CSF from subjects with MS (see table 2). There 
was measurable RLN 3 in the sera of one subject with MS (100 ng/ml, P<0.05) and 
in the CSF of two further subjects with MS (1.318 ng/ml,P<0.05 and 12.587 ng/ml, 
P<0.05). 
Discussion
The presence of RLN3 in both the sera and CSF of subjects with MS could be due 
to production in the CNS and by adipocytes (Yamamoto et al, 2014). Although most 
of the post mortem samples used in this study were collected between 2-5.5 hours 
after death. It is possible that the absence of measurable relaxin levels in some sub-
jects could be due to degradation.
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In contrast, the presence of RLN1 in the sera and CSF of some of the subjects with 
MS is intriguing. Prior to this study RLN1 has not been associated with any function 
and some have postulated that RLN1 may be a pseudogene (Feijóo-Bandín, 2017). 
The presence of RLN1 in the sera and CSF of subjects with MS suggests an up-regu-
lation of expression in these subjects. Which would indicate that RLN is not a pseu-
dogene but plays a role in metabolism. Further, presence of RLN1 in the sera of some 
patients and CSF of others suggests expression in multiple organs. 
The identification of mutations in the DNA sequence of RLN1 from subjects with 
MS is of interest (Garvin and Burns, 2016). These mutations are clustered in the cod-
ing region for the binding motif of RLN1. Leading to the hypothesis that RLN1 in 
subjects with MS may not be fully functional. In this case, the production of RLN2 
during the later stages of pregnancy would obviate RLN1. And may play a role in the 
remission of symptoms during this time. Clearly, more work is needed to characterize 
the role of RLN1 in MS, if any.  
The interest in RLN and MS is further spurred on by its diverse modes of action 
(Bathgate et al, 2013). The ability of RLN to act as a ligand for the glucocorticoid 
receptor (Dschietzig, 2004), PPARg (Singh, 2010) and to modulate the immune system 
are areas of intense research in MS (Frischer et al, 2009).
Table 2. Relaxin Levels in Sera and CSF.
Sample Diagnosis RLN 1 (ng/ml) RLN 3 (ng/ml)Sera P CSF P Sera P CSF P
1 Control - - - -
2 Control - - - -
3 Control - - - -
4 Control - - - -
5 MS - - - -
6 MS - - - 1.318 P<0.05
7 MS - - - 12.587 P<0.05
8 MS - 147 P<0.05 - -
9 MS - 212 P<0.05 - -
10 MS - - 100 P<0.05 -
11 MS 179 P<0.05 - - -
12 MS - - - -
13 MS - - - -
14 MS - - - -
15 MS - - - -
16 MS - - - -
Sera and CSF levels of relaxin in MS and controls. No measurable relaxin was detected in either the sera or 
CSF of the controls. In the MS samples 6 subjects had measurable relaxin. These were divided into 2 cohorts. 
Cohort 1 consisted of 3 subjects who had measurable levels of relaxin 1 in sera (179 ng/ml) or CSF (179.5 ng/
ml). Cohort 2 consisted of 3 subjects who had measurable levels of relaxin 3 in sera (100 ng/ml) or CSF (6.95 
ng/ml). The cohorts were distinct as none of the samples contained both relaxin 1 and 3.
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In conclusion, there is some evidence that RLN1 may not be fully functional in 
subjects with MS. If so, then decreased RLN1 activity could play a role in the patho-
genesis of the disease. The increased expression of RLN2 during pregnancy would 
obviate the need for RLN1. This may play a role in the remission of symptoms seen 
during pregnancy. And raises the possibility of using relaxin as a novel therapeutic 
agent in subjects with MS.
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